erations from CD10 recognition (Far et al. Immunol 2021, PLoS 37:28561.6, (3) dendritic cells (DC)-based vaccine induced long non-coding RNAs (lncRNAs) in cancer patients. (4) IL-10 and IL-22: two different and complementary mechanisms that can modulate antitumor responses and can be targeted by specific strategies in cancer. (5) The combination of tumor-infiltrating lymphocytes (TILs) with checkpoint blockade therapy may provide a new therapeutic option for patients with advanced melanoma.

**References:**

- Far A. et al. *Immunol 2021, PLoS 37:28561.6*
- Ilancheran S, et al. *J Immunol 2018, PLoS 30:22715.2;* and (4) IL-10 and IL-22: two different and complementary mechanisms that can modulate antitumor responses and can be targeted by specific strategies in cancer. (5) The combination of tumor-infiltrating lymphocytes (TILs) with checkpoint blockade therapy may provide a new therapeutic option for patients with advanced melanoma.

**References:**

- Far A. et al. *Immunol 2021, PLoS 37:28561.6*
- Ilancheran S, et al. *J Immunol 2018, PLoS 30:22715.2;* and (4) IL-10 and IL-22: two different and complementary mechanisms that can modulate antitumor responses and can be targeted by specific strategies in cancer. (5) The combination of tumor-infiltrating lymphocytes (TILs) with checkpoint blockade therapy may provide a new therapeutic option for patients with advanced melanoma.

**References:**

- Far A. et al. *Immunol 2021, PLoS 37:28561.6*
- Ilancheran S, et al. *J Immunol 2018, PLoS 30:22715.2;* and (4) IL-10 and IL-22: two different and complementary mechanisms that can modulate antitumor responses and can be targeted by specific strategies in cancer. (5) The combination of tumor-infiltrating lymphocytes (TILs) with checkpoint blockade therapy may provide a new therapeutic option for patients with advanced melanoma.